Outlook Therapeutics Inc (OTLK)

$0.41 +0.01 (2.75%)
Market Cap 33.23M
Revenue (ttm) 1.41M
Net Income (ttm) -62.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,426.95%
Debt to Equity Ratio -0.93
Volume 670,700
Avg Vol 6,559,378
Day's Range N/A - N/A
Shares Out 83.07M
Stochastic %K 16%
Beta 0.11
Analysts Sell
Price Target $6.10

Company Profile

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therap...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 619 3990
Address:
111 S. Wood Avenue, Unit #100, Iselin, United States
25_usa
25_usa Feb. 25 at 3:36 AM
$OTLK https://ir.outlooktherapeutics.com/static-files/0e6b91b1-39aa-43ce-b4d7-356b2da93aac 💰 Potential Gross Peak Sales of Over $600 Million (Europe) This projection is based on: • $3.6B total European anti-VEGF market • ~8.3 million anti-VEGF injections annually • ~2.8 million off-label bevacizumab injections already happening • 1.52 million treated patients • Initial launches in: • Germany (1.7M units/year) • UK (1.3M units/year) • Austria (launched Jan 2026) • Target expansion into France, Italy, Spain, Netherlands, Switzerland, etc
0 · Reply
AnalystLLM
AnalystLLM Feb. 25 at 2:01 AM
$OTLK a fucking sentence and the company agreed to put it into primary end point. what is the problem?
1 · Reply
NxtBgThng
NxtBgThng Feb. 25 at 1:10 AM
$OTLK My reading of this part of the investor presentation is that they are going into the Type A meeting with the exact same evidence that got the CRL. They feel that based on what someone from the FDA told them offline, they can get the FDA to reverse it's decision. Man that's certainly something to chew on. ___________________ "FDA identified a single deficiency based on a purported lack of substantial evidence of effectiveness, and recommended submission of additional confirmatory evidence Company believes this determination is inconsistent with the totality of evidence submitted in the BLA Based on prior FDA discussion in September 2025, Outlook Therapeutics understood that it had aligned with FDA on the requirements for resubmission of the BLA Prior to submitting the Type A meeting request, Outlook Therapeutics conducted informal meetings with the FDA to discuss the CRL"
1 · Reply
AnalystLLM
AnalystLLM Feb. 25 at 12:58 AM
$OTLK Ranibizumab and bevacizumab-vikg are not the same biological substance; a failure to show equivalent performance at Week 8 is not unexpected for two distinct biological substances
0 · Reply
Britbox
Britbox Feb. 25 at 12:54 AM
$OTLK
0 · Reply
Knowledgeworthmore
Knowledgeworthmore Feb. 25 at 12:15 AM
$OTLK its already available in Austria, man they are fast we are going in right direction.
2 · Reply
pfelgueiras
pfelgueiras Feb. 24 at 11:38 PM
$OTLK CORPORATE PRESENTATION FEBRUARY 24, 2026 https://ir.outlooktherapeutics.com/static-files/0e6b91b1-39aa-43ce-b4d7-356b2da93aac See more information about OTLK at https://www.reddit.com/r/OTLK_Investors/
0 · Reply
sta120908
sta120908 Feb. 24 at 9:53 PM
$OTLK
0 · Reply
TheMagnificentFerengi
TheMagnificentFerengi Feb. 24 at 9:35 PM
$OTLK always shits itself at close
1 · Reply
Alder77
Alder77 Feb. 24 at 9:01 PM
$OTLK bad closing as always
1 · Reply
Latest News on OTLK
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland

Feb 19, 2026, 9:00 AM EST - 5 days ago

Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland

Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Feb 17, 2026, 8:05 AM EST - 7 days ago

Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter

Feb 11, 2026, 8:45 AM EST - 13 days ago

Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter

Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development

Jan 6, 2026, 8:35 AM EST - 7 weeks ago

Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development

US FDA declines to approve Outlook Therapeutics' eye disease drug

Dec 31, 2025, 4:23 PM EST - 7 weeks ago

US FDA declines to approve Outlook Therapeutics' eye disease drug

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

Dec 31, 2025, 4:15 PM EST - 7 weeks ago

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

Third Time's The Charm: Outlook Therapeutics Lytenava Heads To FDA, Again

Dec 28, 2025, 8:08 PM EST - 2 months ago

Third Time's The Charm: Outlook Therapeutics Lytenava Heads To FDA, Again

Outlook Therapeutics Announces New Employment Inducement Grants

Dec 26, 2025, 5:00 PM EST - 2 months ago

Outlook Therapeutics Announces New Employment Inducement Grants

Outlook Therapeutics Reports Financial Results for Fiscal Year 2025

Dec 19, 2025, 8:05 AM EST - 2 months ago

Outlook Therapeutics Reports Financial Results for Fiscal Year 2025

Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 9:05 AM EST - 3 months ago

Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Nov 13, 2025, 8:30 AM EST - 3 months ago

Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010

Nov 3, 2025, 8:35 AM EST - 4 months ago

Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010

Outlook Therapeutics Provides Update on Type A Meeting with FDA

Sep 29, 2025, 8:45 AM EDT - 5 months ago

Outlook Therapeutics Provides Update on Type A Meeting with FDA

Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)

Sep 3, 2025, 8:35 AM EDT - 6 months ago

Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)

Outlook Therapeutics Requests Type A Meeting with FDA

Sep 2, 2025, 8:35 AM EDT - 6 months ago

Outlook Therapeutics Requests Type A Meeting with FDA

Outlook Therapeutics plunges more than 52% after FDA rejects wet AMD drug

Aug 28, 2025, 11:51 AM EDT - 6 months ago

Outlook Therapeutics plunges more than 52% after FDA rejects wet AMD drug

FDA Rejects Outlook Therapeutics Eye Drug For Second Time

Aug 28, 2025, 11:15 AM EDT - 6 months ago

FDA Rejects Outlook Therapeutics Eye Drug For Second Time

US FDA declines to approve Outlook Therapeutics' drug for eye condition

Aug 28, 2025, 6:39 AM EDT - 6 months ago

US FDA declines to approve Outlook Therapeutics' drug for eye condition

Outlook Therapeutics: Why The Odds Point To A Favorable FDA Decision

Aug 24, 2025, 9:15 AM EDT - 6 months ago

Outlook Therapeutics: Why The Odds Point To A Favorable FDA Decision

Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update

Aug 14, 2025, 8:05 AM EDT - 6 months ago

Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update

Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

Jul 24, 2025, 9:00 AM EDT - 7 months ago

Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

Outlook Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 22, 2025, 8:45 AM EDT - 7 months ago

Outlook Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

Jul 1, 2025, 8:05 AM EDT - 8 months ago

Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event

Jun 18, 2025, 9:05 AM EDT - 8 months ago

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Jun 10, 2025, 8:05 AM EDT - 9 months ago

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

Jun 2, 2025, 7:00 AM EDT - 9 months ago

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering

May 23, 2025, 6:30 AM EDT - 9 months ago

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants

May 22, 2025, 4:01 PM EDT - 9 months ago

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

May 15, 2025, 4:01 PM EDT - 10 months ago

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Apr 8, 2025, 8:45 AM EDT - 11 months ago

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Feb 28, 2025, 8:05 AM EST - 1 year ago

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 1 year ago

Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

Feb 14, 2025, 8:05 AM EST - 1 year ago

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Feb 4, 2025, 9:05 AM EST - 1 year ago

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

Jan 31, 2025, 8:05 AM EST - 1 year ago

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Jan 23, 2025, 9:05 AM EST - 1 year ago

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Jan 22, 2025, 9:05 AM EST - 1 year ago

Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

Jan 16, 2025, 12:09 PM EST - 1 year ago

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

NVS

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

Jan 16, 2025, 6:00 AM EST - 1 year ago

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Dec 27, 2024, 8:05 AM EST - 1 year ago

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Outlook Therapeutics® Streamlines Operations

Dec 13, 2024, 4:30 PM EST - 1 year ago

Outlook Therapeutics® Streamlines Operations

Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Dec 4, 2024, 8:05 AM EST - 1 year ago

Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Outlook Therapeutics® Announces Executive Leadership Transition

Dec 3, 2024, 4:30 PM EST - 1 year ago

Outlook Therapeutics® Announces Executive Leadership Transition

Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?

Nov 27, 2024, 9:27 AM EST - 1 year ago

Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?

Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial

Nov 27, 2024, 6:50 AM EST - 1 year ago

Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial

Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference

Nov 6, 2024, 8:05 AM EST - 1 year ago

Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference

Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series

Sep 16, 2024, 8:05 AM EDT - 1 year ago

Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series

Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series

Sep 13, 2024, 9:05 AM EDT - 1 year ago

Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series

25_usa
25_usa Feb. 25 at 3:36 AM
$OTLK https://ir.outlooktherapeutics.com/static-files/0e6b91b1-39aa-43ce-b4d7-356b2da93aac 💰 Potential Gross Peak Sales of Over $600 Million (Europe) This projection is based on: • $3.6B total European anti-VEGF market • ~8.3 million anti-VEGF injections annually • ~2.8 million off-label bevacizumab injections already happening • 1.52 million treated patients • Initial launches in: • Germany (1.7M units/year) • UK (1.3M units/year) • Austria (launched Jan 2026) • Target expansion into France, Italy, Spain, Netherlands, Switzerland, etc
0 · Reply
AnalystLLM
AnalystLLM Feb. 25 at 2:01 AM
$OTLK a fucking sentence and the company agreed to put it into primary end point. what is the problem?
1 · Reply
NxtBgThng
NxtBgThng Feb. 25 at 1:10 AM
$OTLK My reading of this part of the investor presentation is that they are going into the Type A meeting with the exact same evidence that got the CRL. They feel that based on what someone from the FDA told them offline, they can get the FDA to reverse it's decision. Man that's certainly something to chew on. ___________________ "FDA identified a single deficiency based on a purported lack of substantial evidence of effectiveness, and recommended submission of additional confirmatory evidence Company believes this determination is inconsistent with the totality of evidence submitted in the BLA Based on prior FDA discussion in September 2025, Outlook Therapeutics understood that it had aligned with FDA on the requirements for resubmission of the BLA Prior to submitting the Type A meeting request, Outlook Therapeutics conducted informal meetings with the FDA to discuss the CRL"
1 · Reply
AnalystLLM
AnalystLLM Feb. 25 at 12:58 AM
$OTLK Ranibizumab and bevacizumab-vikg are not the same biological substance; a failure to show equivalent performance at Week 8 is not unexpected for two distinct biological substances
0 · Reply
Britbox
Britbox Feb. 25 at 12:54 AM
$OTLK
0 · Reply
Knowledgeworthmore
Knowledgeworthmore Feb. 25 at 12:15 AM
$OTLK its already available in Austria, man they are fast we are going in right direction.
2 · Reply
pfelgueiras
pfelgueiras Feb. 24 at 11:38 PM
$OTLK CORPORATE PRESENTATION FEBRUARY 24, 2026 https://ir.outlooktherapeutics.com/static-files/0e6b91b1-39aa-43ce-b4d7-356b2da93aac See more information about OTLK at https://www.reddit.com/r/OTLK_Investors/
0 · Reply
sta120908
sta120908 Feb. 24 at 9:53 PM
$OTLK
0 · Reply
TheMagnificentFerengi
TheMagnificentFerengi Feb. 24 at 9:35 PM
$OTLK always shits itself at close
1 · Reply
Alder77
Alder77 Feb. 24 at 9:01 PM
$OTLK bad closing as always
1 · Reply
TheMagnificentFerengi
TheMagnificentFerengi Feb. 24 at 8:48 PM
$OTLK do we have any actual good news today or is it just management letting the price rise again before they continue diluting all the gains?
1 · Reply
Mychiefs1
Mychiefs1 Feb. 24 at 8:47 PM
$OTLK One would think there is a FDA meeting date set.... Be nice if news were released in a more timely fashion....
0 · Reply
Britbox
Britbox Feb. 24 at 8:27 PM
$OTLK Two more weeks and we should hear type A meeting results Will FDA’s new guidance allow them to use Norse 2 alone, with RWE as sufficient support?  
2 · Reply
SilentJoker34
SilentJoker34 Feb. 24 at 7:50 PM
$OTLK
0 · Reply
CrazyChief
CrazyChief Feb. 24 at 6:46 PM
$OTLK
0 · Reply
mountainman5050
mountainman5050 Feb. 24 at 5:43 PM
$OTLK 💪 😆🤳
1 · Reply
FreeRunner
FreeRunner Feb. 24 at 4:43 PM
$OTLK Here's a couple events our new friend at Outlook might consider attending this year in EU...
0 · Reply
Britbox
Britbox Feb. 24 at 4:06 PM
$OTLK and even more evidence of progress 
2 · Reply
shawn45
shawn45 Feb. 24 at 4:01 PM
$OTLK Reason why this time US FDA approval likelihood due to the FDA has changed the entire process for a new medicine approval with only 1 trial required from now on https://www.biospace.com/fda/its-official-fda-will-now-default-to-one-clinical-trial-for-drug-applications
1 · Reply
shawn45
shawn45 Feb. 24 at 3:42 PM
$OTLK $AQST great stocks to watch for 2026 and 2027. US FDA process likelihood. HIDDEN GEMS
2 · Reply
shawn45
shawn45 Feb. 24 at 3:40 PM
$OTLK if this stock goes to 0.75 cents trading, US FDA news will take this stock back to the 1.50 range.
0 · Reply
shawn45
shawn45 Feb. 24 at 3:37 PM
$OTLK Highly likely this stock might heat up soon upon US FDA meeting. Possible US FDA will provide proper guidance this time for OTLK to work on the Tasks and for submission process. Something big could be coming in.
1 · Reply